179 related articles for article (PubMed ID: 24171676)
1. Denosumab and atypical femoral fractures.
Aspenberg P
Acta Orthop; 2014 Feb; 85(1):1. PubMed ID: 24171676
[No Abstract] [Full Text] [Related]
2. Atypical femoral fractures bilaterally in a patient receiving denosumab.
Drampalos E; Skarpas G; Barbounakis N; Michos I
Acta Orthop; 2014 Feb; 85(1):3-5. PubMed ID: 24171686
[No Abstract] [Full Text] [Related]
3. Atypical fracture of the femur in a patient using denosumab--a case report.
Schilcher J; Aspenberg P
Acta Orthop; 2014 Feb; 85(1):6-7. PubMed ID: 24460109
[No Abstract] [Full Text] [Related]
4. Denosumab and atypical femur fractures.
Cating-Cabral MT; Clarke BL
Maturitas; 2013 Sep; 76(1):1-2. PubMed ID: 23835004
[No Abstract] [Full Text] [Related]
5. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.
Selga J; Nuñez JH; Minguell J; Lalanza M; Garrido M
Osteoporos Int; 2016 Feb; 27(2):827-32. PubMed ID: 26501556
[TBL] [Abstract][Full Text] [Related]
6. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.
Thompson RN; Armstrong CL; Heyburn G
Bone; 2014 Apr; 61():44-7. PubMed ID: 24389366
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
Ramchand SK; Chiang CY; Zebaze RM; Seeman E
Osteoporos Int; 2016 Feb; 27(2):821-5. PubMed ID: 26458389
[TBL] [Abstract][Full Text] [Related]
8. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
Adler RA
Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
[TBL] [Abstract][Full Text] [Related]
9. Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis-a case report.
Piponov HI; Goldstein JM; Eisenberg GM
Osteoporos Int; 2020 Nov; 31(11):2263-2267. PubMed ID: 32561954
[TBL] [Abstract][Full Text] [Related]
10. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
Horning JA; Czajka J; Uhl RL
Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
[No Abstract] [Full Text] [Related]
11. [Diphosphonate treatment of osteoporosis and risk of atypical femoral fractures].
Schwarz P
Ugeskr Laeger; 2012 Jan; 174(1-2):30. PubMed ID: 22233716
[No Abstract] [Full Text] [Related]
12. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication.
Silverman S; Kupperman E; Bukata S
Cleve Clin J Med; 2018 Nov; 85(11):885-893. PubMed ID: 30395525
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
Capozzi A; Lello S; Pontecorvi A
Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
[TBL] [Abstract][Full Text] [Related]
15. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
16. Bilateral femur fractures associated with short-term bisphosphonate use.
Rifai A; Pourtaheri S; Carbone A; Callaghan JJ; Stadler CM; Record N; Issa K
Orthopedics; 2015 Feb; 38(2):e139-42. PubMed ID: 25665120
[TBL] [Abstract][Full Text] [Related]
17. How Long to Treat with Denosumab.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2015 Dec; 13(6):415-20. PubMed ID: 26474564
[TBL] [Abstract][Full Text] [Related]
18. [Innovations in the treatment of osteoporosis].
Tsourdi E; Hofbauer LC
Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
[No Abstract] [Full Text] [Related]
19. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
McCloskey EV; Johansson H; Oden A; Austin M; Siris E; Wang A; Lewiecki EM; Lorenc R; Libanati C; Kanis JA
J Bone Miner Res; 2012 Jul; 27(7):1480-6. PubMed ID: 22431426
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Boonen A; Dirksen CD; Ben Sedrine W; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):19-28. PubMed ID: 23402442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
